Isleworth Healthcare Acquisition Corp. (ISLE)
Chart Events
Performance Outlook
| Previous Close | 9.96 |
| Open | 9.95 |
| Bid | 9.94 x 900 |
| Ask | 10.00 x 1400 |
| Day's Range | 9.94 - 9.96 |
| 52 Week Range | 9.66 - 9.96 |
| Volume | |
| Avg. Volume | 54,900 |
| Market Cap | 260.602M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 62.97 |
| EPS (TTM) | 0.16 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ISLE
Related Research
- Isleworth Healthcare AcquisitioSTN: What does Argus have to say about STN?STANTEC INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat3 days agoArgus Research
- PR Newswire
ISLEWORTH AND CYTOVIA TERMINATE MERGER AGREEMENT
Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agr
- PR Newswire
Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress
Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.
- PR Newswire
Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress
Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online.
